WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
DK3456831T3
(da)
|
2013-04-16 |
2021-09-06 |
Regeneron Pharma |
Målrettet modifikation af rottegenom
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
WO2015040402A1
(en)
|
2013-09-18 |
2015-03-26 |
Kymab Limited |
Methods. cells & organisms
|
US10584358B2
(en)
|
2013-10-30 |
2020-03-10 |
North Carolina State University |
Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
|
LT3066201T
(lt)
|
2013-11-07 |
2018-08-10 |
Editas Medicine, Inc. |
Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
|
AU2014348657A1
(en)
|
2013-11-13 |
2016-05-19 |
Novartis Ag |
mTOR inhibitors for enhancing the immune response
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
RU2685914C1
(ru)
|
2013-12-11 |
2019-04-23 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
JP2017503485A
(ja)
|
2013-12-12 |
2017-02-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
遺伝子産物の発現、構造情報、及び誘導性モジュラーcas酵素を変更するためのcrispr−cas系並びに方法
|
US9840699B2
(en)
|
2013-12-12 |
2017-12-12 |
President And Fellows Of Harvard College |
Methods for nucleic acid editing
|
KR20230076867A
(ko)
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
DK3105328T3
(da)
|
2014-02-11 |
2020-07-13 |
Univ Colorado Regents |
Multiplexet genom manipulation ved hjælp af CRISPR
|
PL3105317T3
(pl)
|
2014-02-14 |
2019-02-28 |
Cellectis |
Komórki do immunoterapii zaprojektowane do celowania antygenu obecnego zarówno na komórkach odpornościowych, jak i komórkach patologicznych
|
CN106460003A
(zh)
|
2014-04-08 |
2017-02-22 |
北卡罗来纳州立大学 |
用于使用crispr相关基因rna引导阻遏转录的方法和组合物
|
AU2015245469B2
(en)
*
|
2014-04-11 |
2020-11-12 |
Cellectis |
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
|
JP2017513477A
(ja)
*
|
2014-04-14 |
2017-06-01 |
マックスサイト インコーポレーティッド |
ゲノムdnaを改変するための方法および組成物
|
US20170175128A1
(en)
*
|
2014-04-18 |
2017-06-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
KR20170032406A
(ko)
|
2014-07-15 |
2017-03-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 조작된 세포
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
EP3633032A3
(en)
|
2014-08-28 |
2020-07-29 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
EA201790953A1
(ru)
*
|
2014-10-31 |
2017-10-31 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Изменение экспрессии гена в cart-клетках и их применения
|
ES2692206T3
(es)
|
2014-11-26 |
2018-11-30 |
Miltenyi Biotec Gmbh |
Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades
|
GB201421096D0
(en)
*
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
KR102629128B1
(ko)
|
2014-12-03 |
2024-01-25 |
애질런트 테크놀로지스, 인크. |
화학적 변형을 갖는 가이드 rna
|
SG11201704549UA
(en)
|
2014-12-05 |
2017-07-28 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
CN113683711A
(zh)
|
2014-12-05 |
2021-11-23 |
纪念斯隆-凯特琳癌症中心 |
靶向g-蛋白偶联受体的嵌合抗原受体及其用途
|
KR20170108946A
(ko)
*
|
2014-12-05 |
2017-09-27 |
메모리얼 슬로안-케터링 캔서 센터 |
Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도
|
SI3226897T1
(sl)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
CN107206077B
(zh)
|
2014-12-05 |
2021-06-08 |
纪念斯隆-凯特琳癌症中心 |
靶向g-蛋白偶联受体的抗体和使用方法
|
WO2016097231A2
(en)
*
|
2014-12-17 |
2016-06-23 |
Cellectis |
INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
US20190054117A1
(en)
*
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
CA2973525C
(en)
*
|
2015-01-26 |
2021-12-14 |
Cellectis |
Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy
|
US20190388469A1
(en)
*
|
2015-01-30 |
2019-12-26 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
EP3253866A1
(en)
*
|
2015-02-06 |
2017-12-13 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
HRP20220890T1
(hr)
|
2015-02-06 |
2022-10-14 |
National University Of Singapore |
Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
WO2016137949A1
(en)
*
|
2015-02-23 |
2016-09-01 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
BR112017018224A2
(pt)
*
|
2015-03-11 |
2018-04-17 |
Cellectis |
métodos para manipulação de célula t alogênica para aumentar sua persistência e/ou implante em pacientes
|
US20180080051A1
(en)
*
|
2015-03-31 |
2018-03-22 |
Exeligen Scientific, Inc. |
Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism
|
JP6873911B2
(ja)
|
2015-04-06 |
2021-05-19 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
初代細胞において標的核酸の遺伝子調節を誘導するためにインビトロで行う方法
|
CN107980059B
(zh)
*
|
2015-04-13 |
2022-11-11 |
美克斯细胞有限公司 |
用于修饰基因组dna的方法和组合物
|
US11390860B2
(en)
|
2015-04-13 |
2022-07-19 |
The University Of Tokyo |
Set of polypeptides exhibiting nuclease activity or nickase activity with dependence on light or in presence of drug or suppressing or activating expression of target gene
|
PE20171653A1
(es)
|
2015-04-13 |
2017-11-13 |
Pfizer |
Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b
|
JP2018515123A
(ja)
|
2015-05-18 |
2018-06-14 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
|
WO2016185443A1
(en)
|
2015-05-20 |
2016-11-24 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
TWI806815B
(zh)
|
2015-05-20 |
2023-07-01 |
美商博德研究所有限公司 |
共有之gata3相關之腫瘤特異性新抗原
|
CN108026536A
(zh)
|
2015-05-29 |
2018-05-11 |
北卡罗来纳州立大学 |
使用crispr核酸筛选细菌、古细菌、藻类和酵母的方法
|
CA2986060A1
(en)
*
|
2015-05-29 |
2016-12-08 |
Valerie Odegard |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
FI3307872T3
(fi)
|
2015-06-15 |
2023-10-16 |
Univ North Carolina State |
Menetelmiä ja koostumuksia nukleiinihappojen ja rna-pohjaisten antimikrobien tehokkaaseen antamiseen
|
CA2989831A1
(en)
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for genomic editing
|
EP3310931B1
(en)
*
|
2015-06-17 |
2021-11-17 |
The UAB Research Foundation |
Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
WO2016205688A2
(en)
|
2015-06-18 |
2016-12-22 |
Bowles Robert D |
Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
|
JP2018519811A
(ja)
|
2015-06-29 |
2018-07-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
修飾crispr rna及び修飾単一crispr rnaならびにその使用
|
MA42895A
(fr)
*
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
US20170020922A1
(en)
*
|
2015-07-16 |
2017-01-26 |
Batu Biologics Inc. |
Gene editing for immunological destruction of neoplasia
|
EP3325018A4
(en)
|
2015-07-22 |
2019-04-24 |
Duke University |
HIGH EFFICIENCY SCREENING OF REGULATORY ELEMENT FUNCTION USING EPIGENOUS EDITING TECHNOLOGIES
|
JP7409773B2
(ja)
|
2015-07-31 |
2024-01-09 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
改変された細胞および治療の方法
|
CA2994746A1
(en)
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
IL288662B2
(en)
|
2015-08-25 |
2023-09-01 |
Univ Duke |
Preparations and methods for improving specificity in genomic engineering using RNA-guided endonucleases
|
CN108135932A
(zh)
*
|
2015-08-28 |
2018-06-08 |
宾夕法尼亚大学董事会 |
表达嵌合细胞内信号传导分子的细胞的方法和组合物
|
WO2017049266A2
(en)
*
|
2015-09-18 |
2017-03-23 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
|
WO2017049208A1
(en)
*
|
2015-09-18 |
2017-03-23 |
The General Hospital Corporation Dba Massachusetts General Hospital |
Localized delivery of anti-fugetactic agent for treatment of cancer
|
WO2017058751A1
(en)
|
2015-09-28 |
2017-04-06 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
WO2017059241A1
(en)
*
|
2015-10-02 |
2017-04-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
EP3940070A1
(en)
|
2015-10-05 |
2022-01-19 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
EP3359184B1
(en)
|
2015-10-05 |
2020-05-06 |
Precision Biosciences, Inc. |
Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
CN108778343A
(zh)
*
|
2015-10-16 |
2018-11-09 |
天普大学-联邦高等教育*** |
利用cpf1进行rna向导的基因编辑的方法和组合物
|
IL300420B1
(en)
|
2015-10-16 |
2024-05-01 |
Univ Columbia |
Preparations and methods for inhibiting antigens of a certain lineage
|
WO2017070429A1
(en)
*
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
CN108699116A
(zh)
|
2015-10-23 |
2018-10-23 |
哈佛大学的校长及成员们 |
用于基因编辑的演化的cas9蛋白
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
EP3370741A4
(en)
*
|
2015-11-04 |
2019-04-24 |
The Trustees of The University of Pennsylvania |
METHODS AND COMPOSITIONS FOR EDITING GENES IN HEMATOPOIETIC STEM CELLS
|
EP3377086B1
(en)
|
2015-11-19 |
2024-05-01 |
The Brigham and Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
SG11201804656PA
(en)
|
2015-12-04 |
2018-06-28 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting fc receptor-like 5 and methods of use
|
BR112018011089A2
(pt)
*
|
2015-12-04 |
2018-12-04 |
Intellia Therapeutics Inc |
composições e métodos para a imuno-oncologia
|
AU2016369490C1
(en)
*
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
CN106967685B
(zh)
*
|
2016-01-13 |
2020-06-02 |
北京马力喏生物科技有限公司 |
共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
|
CN106967681B
(zh)
*
|
2016-01-13 |
2020-06-05 |
北京马力喏生物科技有限公司 |
治疗脑胶质母细胞瘤的治疗组合物
|
WO2017125830A1
(en)
|
2016-01-21 |
2017-07-27 |
Pfizer Inc. |
Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
|
CA3016331A1
(en)
*
|
2016-03-04 |
2017-09-08 |
Editas Medicine, Inc. |
Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
US20190161530A1
(en)
*
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
CA3020923A1
(en)
|
2016-04-15 |
2017-10-19 |
Memorial Sloan Kettering Cancer Center |
Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
|
EP3429633B1
(en)
*
|
2016-04-15 |
2021-02-24 |
Cellectis |
A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
CN107304434A
(zh)
*
|
2016-04-25 |
2017-10-31 |
上海宇玫博生物科技有限公司 |
一种免疫细胞治疗的双功能新型载体
|
EP3452499A2
(en)
*
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
CA3029254A1
(en)
|
2016-06-24 |
2017-12-28 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods for generating barcoded combinatorial libraries
|
US11466291B2
(en)
|
2016-07-06 |
2022-10-11 |
Cellectis |
Sequential gene editing in primary immune cells
|
US11242376B2
(en)
|
2016-08-02 |
2022-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
EP3497214B1
(en)
|
2016-08-09 |
2023-06-28 |
President and Fellows of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
WO2018031762A1
(en)
*
|
2016-08-10 |
2018-02-15 |
Duke University |
Compositions, systems and methods for programming immune cell function through targeted gene regulation
|
SG11201901184QA
(en)
|
2016-08-12 |
2019-03-28 |
Toolgen Inc |
Manipulated immunoregulatory element and immunity altered thereby
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
EP3512541A1
(en)
|
2016-09-14 |
2019-07-24 |
Janssen Biotech, Inc. |
Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
|
JP2019536437A
(ja)
|
2016-10-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Hpv特異的結合分子
|
EP3848392A1
(en)
|
2016-10-07 |
2021-07-14 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
CA3039928A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
WO2018075664A1
(en)
|
2016-10-18 |
2018-04-26 |
Regents Of The University Of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
CA3040048A1
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
US20230138915A1
(en)
*
|
2016-10-19 |
2023-05-04 |
Cellectis |
TAL- effector nuclease (TALEN) -MODIFIED ALLOGENIC CELLS SUITABLE FOR THERAPY
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
WO2018073391A1
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
WO2018073394A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
WO2018080541A1
(en)
|
2016-10-31 |
2018-05-03 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogennous foxp3 gene
|
WO2018087276A1
(en)
|
2016-11-10 |
2018-05-17 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Or10h1 modulators and uses thereof
|
EP3321280B8
(en)
|
2016-11-10 |
2021-03-10 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases
|
WO2018098306A1
(en)
|
2016-11-22 |
2018-05-31 |
National University Of Singapore |
Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
|
MX2019006090A
(es)
|
2016-11-23 |
2019-08-21 |
Novartis Ag |
Metodos para mejorar la respuesta inmune con everolimus, dactolisib o ambos.
|
EP3559214A1
(en)
*
|
2016-12-21 |
2019-10-30 |
UCL Business PLC |
Therapeutic cells
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
CN107760680B
(zh)
*
|
2016-12-28 |
2020-09-22 |
北京微旋基因技术有限公司 |
特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
EP3573657A4
(en)
*
|
2017-01-29 |
2021-04-14 |
Zequn Tang |
IMMUNE MODULATION METHODS AGAINST FOREIGN ANTIGENS AND / OR AUTOANTIGENS
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
CN110612119A
(zh)
|
2017-02-07 |
2019-12-24 |
西雅图儿童医院(Dba西雅图儿童研究所) |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
CN110461335A
(zh)
|
2017-02-17 |
2019-11-15 |
弗雷德哈钦森癌症研究中心 |
用于治疗bcma相关癌症和自身免疫性失调的联合疗法
|
CN110582288A
(zh)
|
2017-02-28 |
2019-12-17 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
US11975029B2
(en)
|
2017-02-28 |
2024-05-07 |
Vor Biopharma Inc. |
Compositions and methods for inhibition of lineage specific proteins
|
EP3592381A1
(en)
*
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Cancer vaccine
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
EP3592777A1
(en)
|
2017-03-10 |
2020-01-15 |
President and Fellows of Harvard College |
Cytosine to guanine base editor
|
CN110832075A
(zh)
|
2017-03-22 |
2020-02-21 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
US11268082B2
(en)
|
2017-03-23 |
2022-03-08 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable DNA binding proteins
|
US11690873B2
(en)
|
2017-03-31 |
2023-07-04 |
Cellectis Sa |
Universal chimeric antigen receptor T cells specific for CD22
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
|
EP3391907B8
(en)
|
2017-04-20 |
2020-03-04 |
iOmx Therapeutics AG |
Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
|
JP7235391B2
(ja)
*
|
2017-05-08 |
2023-03-08 |
ツールゲン インコーポレイテッド |
人工的に操作された免疫細胞
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
WO2019097305A2
(en)
|
2017-05-12 |
2019-05-23 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
EP3630980B1
(en)
*
|
2017-06-01 |
2023-11-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cell preparation and uses thereof
|
AU2018278321A1
(en)
|
2017-06-02 |
2019-11-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting FLT3
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
KR20240027153A
(ko)
|
2017-06-15 |
2024-02-29 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
표적화된 비-바이러스 dna 삽입
|
KR20200019231A
(ko)
*
|
2017-06-22 |
2020-02-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
조절 면역 세포를 제조하기 위한 방법 및 이의 용도
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US11235004B2
(en)
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
EP3645036A1
(en)
|
2017-06-30 |
2020-05-06 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
EP3645038A1
(en)
|
2017-06-30 |
2020-05-06 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
JP7280238B2
(ja)
|
2017-07-17 |
2023-05-23 |
ヤンセン バイオテツク,インコーポレーテツド |
フィブロネクチンiii型ドメインに対する抗原結合領域及びその使用方法
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
CN111194350A
(zh)
*
|
2017-09-18 |
2020-05-22 |
博雅辑因(北京)生物科技有限公司 |
一种基因编辑t细胞及其用途
|
AU2018336791A1
(en)
|
2017-09-19 |
2020-03-12 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor T cell therapy and uses thereof
|
JP2020535802A
(ja)
|
2017-09-21 |
2020-12-10 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
標的化核酸編集のための系、方法、及び組成物
|
EP3692063A1
(en)
|
2017-10-03 |
2020-08-12 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
CA3084476A1
(en)
*
|
2017-10-19 |
2019-04-25 |
Cellectis |
Targeted gene integration of nk inhibitors genes for improved immune cells therapy
|
IL274179B2
(en)
|
2017-10-27 |
2024-02-01 |
Univ California |
Targeted replacement of endogenous T cell receptors
|
JP2021501156A
(ja)
*
|
2017-10-27 |
2021-01-14 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
T細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定
|
US11623961B2
(en)
|
2017-11-01 |
2023-04-11 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
CN111295189B
(zh)
|
2017-11-01 |
2023-09-15 |
艾洛基治疗公司 |
修饰的胱天蛋白酶-9多肽及其使用方法
|
BR112020008638A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
|
CN109750035B
(zh)
*
|
2017-11-02 |
2020-06-05 |
上海邦耀生物科技有限公司 |
靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA
|
US12018080B2
(en)
|
2017-11-13 |
2024-06-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
|
US11738047B2
(en)
|
2017-12-12 |
2023-08-29 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
EP3508499A1
(en)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
|
CA3088234A1
(en)
|
2018-01-12 |
2019-07-18 |
Curocell Inc. |
Enhanced immune cells using dual shrna and composition including the same
|
SG11202006886VA
(en)
|
2018-01-22 |
2020-08-28 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Methods of use for car t cells
|
PT110526B
(pt)
|
2018-01-26 |
2021-02-04 |
Univ Nova De Lisboa |
Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
|
CA3089318A1
(en)
|
2018-02-01 |
2019-08-08 |
Pfizer Inc. |
Chimeric antigen receptors targeting cd70
|
TW201934580A
(zh)
|
2018-02-01 |
2019-09-01 |
美商輝瑞大藥廠 |
對cd70具特異性抗體及其用途
|
WO2019166946A1
(en)
|
2018-02-28 |
2019-09-06 |
Pfizer Inc. |
Il-15 variants and uses thereof
|
EP3775229A4
(en)
|
2018-03-27 |
2021-12-15 |
The Trustees Of The University Of Pennsylvania |
MODIFIED IMMUNE CELLS WITH IMPROVED FUNCTIONS AND SCREENING PROCEDURES FOR THIS
|
CA3095084A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
EP3773908A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
MX2020010459A
(es)
|
2018-04-05 |
2021-01-20 |
Juno Therapeutics Inc |
Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas.
|
CN112218889A
(zh)
|
2018-04-12 |
2021-01-12 |
精密生物科学公司 |
对人T细胞受体α恒定区基因具有特异性的优化的工程化核酸酶
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
SG11202007878UA
(en)
|
2018-04-27 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Expression of foxp3 in edited cd34+ cells
|
CA3099401A1
(en)
*
|
2018-05-07 |
2019-11-14 |
The Regents Of The University Of California |
Compositions and methods for modifying regulatory t cells
|
JP2021522820A
(ja)
|
2018-05-11 |
2021-09-02 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
癌を治療するための方法及び組成物
|
KR20210045360A
(ko)
|
2018-05-16 |
2021-04-26 |
신테고 코포레이션 |
가이드 rna 설계 및 사용을 위한 방법 및 시스템
|
EP3793590A4
(en)
*
|
2018-05-17 |
2022-02-16 |
Regents of the University of Minnesota |
DRUG RESISTANT IMMUNE CELLS AND METHODS OF USE
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
WO2019237398A1
(zh)
*
|
2018-06-16 |
2019-12-19 |
深圳市博奥康生物科技有限公司 |
一种特异靶向人CD272基因的gRNA导向序列及其应用
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
SG11202101994XA
(en)
|
2018-08-28 |
2021-03-30 |
Vor Biopharma Inc |
Genetically engineered hematopoietic stem cells and uses thereof
|
US11845958B2
(en)
*
|
2018-09-05 |
2023-12-19 |
Wisconsin Alumni Research Foundation |
Genetically modified genes and cells, and methods of using same for silencing virus gene expression
|
JP2022511345A
(ja)
*
|
2018-09-21 |
2022-01-31 |
カファ セラピューティクス リミテッド |
CRISPR/Casシステムに基づいた細胞の遺伝子編集の方法
|
EP3856763A1
(en)
|
2018-09-28 |
2021-08-04 |
Massachusetts Institute of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
EP3861120A4
(en)
|
2018-10-01 |
2023-08-16 |
North Carolina State University |
RECOMBINANT TYPE I CRISPR-CAS SYSTEM
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
KR20210091160A
(ko)
*
|
2018-10-16 |
2021-07-21 |
인텔리아 테라퓨틱스, 인크. |
면역요법을 위한 조성물 및 방법
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
WO2020109953A1
(en)
|
2018-11-30 |
2020-06-04 |
Janssen Biotech, Inc. |
Gamma delta t cells and uses thereof
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CN109652378B
(zh)
*
|
2018-12-29 |
2020-04-24 |
广州百暨基因科技有限公司 |
一种功能增强的通用型car-t细胞及其制备方法和用途
|
CN109722437B
(zh)
*
|
2018-12-29 |
2020-01-07 |
广州百暨基因科技有限公司 |
一种通用型car-t细胞及其制备方法和用途
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
WO2020191243A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
MX2021011536A
(es)
*
|
2019-03-22 |
2022-02-11 |
Spotlight Therapeutics |
Agente de edición dirigida de genes activos y métodos de uso.
|
MA55797A
(fr)
|
2019-04-30 |
2022-03-09 |
Crispr Therapeutics Ag |
Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19
|
BR112021021075A2
(pt)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
|
KR20220016474A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 cd247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법
|
EP3736330A1
(en)
|
2019-05-08 |
2020-11-11 |
European Molecular Biology Laboratory |
Modified adeno-associated virus (aav) particles for gene therapy
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
JP2022538688A
(ja)
|
2019-07-05 |
2022-09-05 |
イオックス セラピューティクス アーゲー |
IGSF11(VSIG3)のIgC2に結合する抗体及びその使用
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
EP4021937A1
(en)
|
2019-08-27 |
2022-07-06 |
Janssen Biotech, Inc. |
Chimeric antigen receptor system and uses thereof
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
PE20230173A1
(es)
|
2020-03-03 |
2023-02-01 |
Janssen Biotech Inc |
CELULAS T (gama-delta) Y USOS DE ESTAS
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
WO2021188384A1
(en)
*
|
2020-03-14 |
2021-09-23 |
Berkeley Lights, Inc. |
Methods of amplifying paired transcript sequences from single cells
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
EP3910331A1
(en)
|
2020-05-15 |
2021-11-17 |
iOmx Therapeutics AG |
Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたt細胞、関連ポリヌクレオチド、および方法
|
EP4175668A1
(en)
|
2020-07-06 |
2023-05-10 |
iOmx Therapeutics AG |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
EP4185610A2
(en)
|
2020-07-21 |
2023-05-31 |
Allogene Therapeutics, Inc. |
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
|
EP3957720A1
(en)
|
2020-08-21 |
2022-02-23 |
Charité - Universitätsmedizin Berlin |
Immunosuppressant-resistant t-cells for adoptive immunotherapy
|
EP4196572A1
(en)
*
|
2020-08-14 |
2023-06-21 |
Charité - Universitätsmedizin Berlin |
Immunosuppressant-resistant t-cells for adoptive immunotherapy
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
MX2023005446A
(es)
|
2020-11-11 |
2023-07-18 |
European Molecular Biology Laboratory |
Particulas virales modificadas para terapia genica.
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
WO2022132756A1
(en)
*
|
2020-12-14 |
2022-06-23 |
Emendobio Inc. |
Biallelic knockout of trac
|
EP4039808A1
(en)
*
|
2021-02-08 |
2022-08-10 |
Ospedale San Raffaele S.r.l. |
Guide rnas and uses thereof
|
WO2022187406A1
(en)
|
2021-03-03 |
2022-09-09 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
WO2022215978A1
(ko)
*
|
2021-04-05 |
2022-10-13 |
주식회사 셀렌진 |
Pdcd-1 유전자에 상보적인 가이드 rna 및 이의 용도
|
EP4377460A1
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
EP4377459A2
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
AU2022343300A1
(en)
|
2021-09-10 |
2024-04-18 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
KR20230131816A
(ko)
*
|
2022-03-04 |
2023-09-14 |
주식회사 툴젠 |
저면역원성 줄기세포, 줄기세포로부터 분화되거나 유래된 저면역원성 세포및 이의 제조방법
|
US20230372395A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
US20240067968A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|